We have used an integrated transcriptomics and proteomics approach to reveal the extensive dysregulation of the endocytic pathway caused by mutations in LRRK2. Together, our findings across PD LRRK2 models and post-mortem brain tissue from PD patients carrying LRRK2 mutations demonstrate that LRRK2 mutations lead to clear and substantial changes in the endocytic pathway. This evidence concerns the gene LRRK2 and Parkinson disease.